论文部分内容阅读
目的:评价丹栀逍遥散加减治疗2型糖尿病合并抑郁症的疗效.方法:计算机合手工检索数据库,检索截止日期为2016年8月8日.收集应用丹栀逍遥散加减治疗2型糖尿病合并抑郁症的随机对照试验,采用Cochrane协作网提供的偏倚风险评估工具对纳入研究进行质量评估,采用Revman 5.1软件对空腹血糖(FBG)、餐后2h血糖(2h PBG)、糖化血红蛋白(HbA1c)、汉密尔顿焦虑量表(HAMD)、抑郁自评量表(SDS)进行Meta分析.结果:共纳入7个随机对照研究,全部为中文文献,包括490例2型糖尿病合并抑郁症受试者.所纳入文献存在高偏倚风险.Meta分析显示:与对照组比较,应用丹栀逍遥散制剂能降低FBG[MD=-1.04,95％CI(-1.65,-0.43),P=0.000,9]、2 h PBG [MD=-1.45,95％ CI(-1.66,-1.25),P＜0.000,01]、HbA1c [MD =-1.00,95％ CI(-1.48,-0.52),P＜0.000,1]、HAMD[MD=-3.59,95％ CI(-6.33,-0.85),P=0.01]、SDS[MD=-8.61,95％ CI(-9.53,-7.69),P＜0.000,01]水平.结论:应用丹栀逍遥散治疗2型糖尿病合并抑郁症在改善FBG、2 h PBG、HbA1c、HAMD、SDS方面具有优势.但确切结论尚需更多高质量研究加以验证.“,”Objective:To evaluate the clinical effect of Danzhi Xiaoyao powder adjustment on the treatment of type 2 diabetes mellitus complicating depression.Methods:We summarized journals related literature up to April 8th,2016,according to computer search and artificial methods,to search study papers of randomized control trials of Danzhi Xiaoyao powder adjustment on the treatment of type 2 diabetes mellitus complicating depression.Bias risk evaluation tool offered by Cochrane collaboration was applied to do methodo-logieal quality assessment on included studies.Meta-analysis of FBG,2h PBG,HbA1c,HAMD,SDS was applied by software Revman 5.1.Results:A Total of seven studies were included,involving 490 patients.There was high risk of bias.Meta analysis results showed that compared with the control group,Danzhi Xiaoyao powder adjustment can reduce the FBG [MD=-1.04,95％CI (-1.65,-0.43),P=0.000,9],2h PBG [MD=-1.45,95％CI (-1.66,-1.25),P＜0.000,01],HbA1c[MD=-1.00,95％CI (-1.48,-0.52),P＜0.00,01],HAMD [MD=-3.59,95％CI (-6.33,-0.85),P=0.01],SDS [MD=-8.61,95％C1 (-9.53,-7.69),P＜0.000,01].Conclusion:Danzhi Xiaoyao powder adjustment can decrease FBG,2h PBG,HAMD,SDS in patients of type 2 diabetes mellitus complicating depression.But definite conclusion remains to be examined by more high-quality studies.